Integrated Advisors Network LLC Acquires 6,177 Shares of Insulet Corporation $PODD

Integrated Advisors Network LLC lifted its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 15.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,635 shares of the medical instruments supplier’s stock after buying an additional 6,177 shares during the quarter. Integrated Advisors Network LLC’s holdings in Insulet were worth $14,398,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Insulet by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after acquiring an additional 87,845 shares during the period. Geode Capital Management LLC increased its position in shares of Insulet by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock worth $603,211,000 after purchasing an additional 58,309 shares during the last quarter. Norges Bank purchased a new stake in shares of Insulet during the 2nd quarter valued at $324,689,000. Federated Hermes Inc. raised its position in Insulet by 14.3% during the second quarter. Federated Hermes Inc. now owns 723,363 shares of the medical instruments supplier’s stock valued at $227,266,000 after purchasing an additional 90,494 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Insulet by 1.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 681,130 shares of the medical instruments supplier’s stock worth $213,997,000 after buying an additional 6,763 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PODD shares. JPMorgan Chase & Co. reduced their price target on Insulet from $415.00 to $340.00 and set an “overweight” rating on the stock in a research report on Thursday, February 19th. Zacks Research cut shares of Insulet from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Citigroup lowered their price objective on Insulet from $380.00 to $345.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a report on Thursday, January 22nd. Finally, Wells Fargo & Company boosted their target price on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Twenty analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $354.57.

Insulet Trading Up 1.4%

Shares of PODD stock opened at $251.50 on Friday. The company has a market cap of $17.71 billion, a PE ratio of 71.86, a price-to-earnings-growth ratio of 1.48 and a beta of 1.41. The stock’s 50 day simple moving average is $269.07 and its two-hundred day simple moving average is $303.58. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The firm had revenue of $783.80 million during the quarter, compared to analyst estimates of $768.31 million. During the same quarter last year, the business earned $1.15 EPS. The business’s revenue was up 31.2% on a year-over-year basis. Research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity

In related news, Director Michael R. Minogue purchased 2,030 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.39% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.